Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RAD52 | P43351 | 2/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | APP | P05067 | 2/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362771 | 1.00 | MAPT (1.00) | MAPTGAAATMMAPKAPK2CYP2D6 | |
| SCHEMBL9452123 | 0.85 | MAPT (0.74) | MAPTGAAATMCYP2D6CYP1A2 | |
| SCHEMBL12430792 | 0.85 | MAPT (0.74) | MAPTGAAATMCYP2D6CYP1A2 | |
| SCHEMBL5309628 | 0.85 | MAPT (0.74) | MAPTGAAATMCYP2D6CYP1A2 | |
| SCHEMBL21346893 | 0.85 | MAPT (0.74) | MAPTGAAATMCYP2D6CYP1A2 | |
| SCHEMBL30179800 | 0.85 | GAA (0.73) | MAPTGAAATMCYP2D6CYP1A2 | |
| SCHEMBL2011565 | 0.85 | GAA (0.73) | MAPTGAAATMCYP2D6CYP1A2 | |
| SCHEMBL21121733 | 0.85 | MAPT (0.73) | MAPTGAAATMCYP2D6CYP1A2 | |
| SCHEMBL9480795 | 0.83 | MAPT (0.71) | MAPTGAAATMMAPKAPK2CYP2D6 | |
| SCHEMBL27878984 | 0.83 | MAPT (0.71) | MAPTGAAATMMAPKAPK2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481806-B1 | 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS | INST NAT SANTE RECH MED (FR) | 2023-06-07 | — | — | EP | claimed |
| EP-3735407-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2020-11-11 | — | — | EP | claimed |
| WO-2019134969-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-07-11 | — | — | WO | claimed |
| US-20160031854-A1 | ACTIVATION OR REACTIVATION OF ACHE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-04 | — | — | US | claimed |
| WO-2014210168-A1 | ACTIVATION OR REACTIVATION OF ACHE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-31 | — | — | WO | claimed |
| WO-2014113495-A1 | ACTIVATION OR REACTIVATION OF ACHE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-24 | — | — | WO | claimed |
| US-20230301981-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230301981-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-4164646-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-04-19 | — | — | EP | disclosed |
| WO-2021257273-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257273-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-23 | — | — | WO | disclosed |
| EP-3735407-A1 | SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019173482-A1 | 4-AMINOQUINOLINE COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | UNIVERSITE LILLE 1 - SCIENCES ET TECHNOLOGIES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | UNIVERSITE LILLE 1 - SCIENCES ET TECHNOLOGIES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | UNIVERSITE LILLE 1 - SCIENCES ET TECHNOLOGIES (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2513062-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | Institut National de la Santé et de la Recherche Médicale (FR) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073322-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073322-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-06-23 | — | — | WO | disclosed |
| US-4421920-A | AMINATION, AROMATIZATION, RUTHENIUM CATALYST | RHONE-POULENC SANTE (FR) | 1983-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | APP, BACE1, PSEN1 | MAPT 20/4885GAA 537/4885ATM 2757/4885 |
| US-20230301981-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | MAPT 3896/4885GAA 1014/4885ATM 690/4885 |
| US-20160031854-A1 | ACTIVATION OR REACTIVATION OF ACHE | ACHE, BCHE, CHAT | MAPT 2917/4885GAA 337/4885ATM 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.